Concomitant Radiotherapy and New Drugs in Metastatic Breast Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorFondazione Policlinico Universitario Campus Bio-Medico
About this trial
The primary objective of the study is to describe the tolerance profile of radiation treatments performed during systemic treatment with new drugs (molecular targeted therapies, immunotherapy, others).
Eligibility criteria
Qualifiers
Patients suffering from stage IV breast cancer
Ongoing systemic treatment including: molecular targeted therapy, conjugated antibodies, monoclonal antibodies, tyrosine kinase inhibitors, immunotherapy (immunocheckpoint inhibitors)
Candidates for radiation treatment (both palliative and curative).
Disqualifiers
Previous radiation treatment on the same site
Absolute contraindications to radiotherapy
Systemic treatment administered as part of a clinical trial
Trial design
Treatments tested in this trial
- Radiotherapy
Treatment groups
300 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov